PMID- 24135241
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20181202
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 9 Suppl 2
DP  - 2013 Sep
TI  - A severe dermatologic adverse effect related with gefitinib: case report and 
      review of the literature.
PG  - S110-3
LID - 10.4103/0973-1482.119123 [doi]
AB  - Gefitinib, a selective inhibitor of the epidermal growth factor receptor-tyrosine 
      kinase, it's one of the most frequent drug-related adverse effects (AEs) reported 
      in literature is dermatologic AEs. We report, a case of severe cutaneous adverse 
      reactions induced by gefitinib as second-line treatment in a male patient with 
      advanced non-small cell lung cancer after 1 month of treatment. Although tumor 
      shrunk and patient got benefit from the treatment, gefitinib had to be stopped 
      right away. We managed the symptoms of rash with a variety of treatments, 
      including topical ethacridine lactate, antihistamine and so on. After the rash 
      improved, we found his tumor were progress. Then he took gefitinib again without 
      severe skin toxicity or disease progression. We think the development of 
      gefitinib-induced rash may be a sign of effective and administrating it again 
      maybe relieves the degree of rash.
FAU - Li, Yuan-Qing
AU  - Li YQ
AD  - Department of Integration of TCM and Western Medicine, Key Laboratory of 
      Carcinogenesis and Translational Research (Ministry of Education), Peking 
      University Cancer Hospital and Institute, Beijing, China.
FAU - Sun, Hong
AU  - Sun H
FAU - Xue, Dong
AU  - Xue D
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Bone Neoplasms/drug therapy/secondary
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/secondary
MH  - Edema/chemically induced/*diagnosis
MH  - Erythema/chemically induced/*diagnosis
MH  - Gefitinib
MH  - Humans
MH  - Lung Neoplasms/drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Quinazolines/*adverse effects/therapeutic use
EDAT- 2013/10/30 06:00
MHDA- 2014/05/28 06:00
CRDT- 2013/10/19 06:00
PHST- 2013/10/19 06:00 [entrez]
PHST- 2013/10/30 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - JCanResTher_2013_9_5_110_119123 [pii]
AID - 10.4103/0973-1482.119123 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2013 Sep;9 Suppl 2:S110-3. doi: 10.4103/0973-1482.119123.